{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T06:32:38Z","timestamp":1785047558904,"version":"3.55.0"},"reference-count":19,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T00:00:00Z","timestamp":1692230400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vox Sanguinis"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background and Objectives<\/jats:title><jats:p>ABO antigens are among the most immunogenic, but the haemolytic risks of ABO incompatibilities involving a donor with a weak ABO phenotype are little documented.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>This retrospective case series assessed the incidence of acute haemolytic transfusion reaction (AHTR) among ABO\u2010incompatible recipients of A<jats:sub>3<\/jats:sub> blood in Qu\u00e9bec (Canada). Transfusion safety officers reported laboratory AHTR indicators measured \u226424\u2009h pre\u2010 and post\u2010transfusion. Because the AHTR case definition of Qu\u00e9bec's Hemovigilance System (QHS) leaves significant room for clinical judgement, a two\u2010step approach was used to assess potential cases: Step 1 consisted in a highly sensitive\u2014but unspecific\u2014initial screen that identified all candidate cases per QHS case definition, and Step 2 consisted in a detailed review of candidate cases by two haematologists.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Nine donors initially typed as Group B (<jats:italic>N<\/jats:italic>\u2009=\u20091) or O (<jats:italic>N<\/jats:italic>\u2009=\u20098) were subsequently found to display an A<jats:sub>3<\/jats:sub>B or A<jats:sub>3<\/jats:sub>O phenotype. Eighty\u2010one recipients received ABO\u2010incompatible blood, including 53 (65.4%) with interpretable data. Of these, 29 (54.7%) were classified as candidate cases after Step 1. Following Step 2, no conclusive evidence of AHTR was found: Abnormal pre\u2010 versus post\u2010transfusion changes appeared modest, within normal range, insufficient to ascertain AHTR, or were consistent with a pre\u2010existing condition unrelated to AHTR. Two candidate cases had a QHS\u2010reported transfusion reaction; both were unrelated to AHTR.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In this case series, no conclusive evidence of serious AHTR was found among ABO\u2010incompatible recipients who were inadvertently transfused with A<jats:sub>3<\/jats:sub> blood.<\/jats:p><\/jats:sec>","DOI":"10.1111\/vox.13503","type":"journal-article","created":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T09:11:47Z","timestamp":1692263507000},"page":"854-862","source":"Crossref","is-referenced-by-count":1,"title":["Incidence of acute haemolytic transfusion reaction among <scp>ABO<\/scp>\u2010incompatible recipients transfused with <scp>A<sub>3<\/sub><\/scp> blood: A case series"],"prefix":"10.1111","volume":"118","author":[{"given":"Catherine","family":"Latour","sequence":"first","affiliation":[{"name":"Transfusion Medicine H\u00e9ma\u2010Qu\u00e9bec  Montr\u00e9al Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amaury","family":"Gaussen","sequence":"additional","affiliation":[{"name":"Medical Affairs and Innovation H\u00e9ma\u2010Qu\u00e9bec  Qu\u00e9bec City Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Beaudoin","sequence":"additional","affiliation":[{"name":"Quality Control and Development H\u00e9ma\u2010Qu\u00e9bec  Montr\u00e9al Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8144-1443","authenticated-orcid":false,"given":"Gabriel Andr\u00e9","family":"Leiva\u2010Torres","sequence":"additional","affiliation":[{"name":"Transfusion Medicine H\u00e9ma\u2010Qu\u00e9bec  Montr\u00e9al Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0832-0792","authenticated-orcid":false,"given":"Samuel","family":"Rochette","sequence":"additional","affiliation":[{"name":"Medical Affairs and Innovation H\u00e9ma\u2010Qu\u00e9bec  Montr\u00e9al Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Robitaille","sequence":"additional","affiliation":[{"name":"Transfusion Medicine H\u00e9ma\u2010Qu\u00e9bec  Montr\u00e9al Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,8,17]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1802338"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01313-6"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-075067572-7.50033-3"},{"key":"e_1_2_9_5_1","unstructured":"Comit\u00e9 de Biovigilance du Qu\u00e9bec.Rapport 2016\u20102017. [cited 2022 Jan 11]. Available from:https:\/\/publications.msss.gouv.qc.ca\/msss\/fichiers\/2020\/20-933-03W.pdf"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1309\/X59TAAYPEPCNBLUJ"},{"key":"e_1_2_9_7_1","first-page":"38","article-title":"A hemolytic reaction due to the transfusion of Ax blood","volume":"54","author":"Schmidt PJ","year":"1959","journal-title":"J Lab Clin Med"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1159\/000356378"},{"key":"e_1_2_9_9_1","unstructured":"Institut National de Sant\u00e9 Publique du Qu\u00e9bec.Guide de d\u00e9claration des \u00e9v\u00e9nements ind\u00e9sirables associ\u00e9s \u00e0 la transfusion de produits sanguins.2017."},{"key":"e_1_2_9_10_1","unstructured":"Choosing Wisely Canada.Why give two when one will do?\u2014A toolkit for reducing unnecessary red blood cell transfusions in hospitals.2019."},{"key":"e_1_2_9_11_1","unstructured":"NawejKI LambertG Unit\u00e9 Surveillance \u00c9valuation de Risque et Contr\u00f4le des Maladies Infectieuses Direction des Risques Biologiques.Surveillance des erreurs et r\u00e9actions transfusionnelles au Qu\u00e9bec.2019[cited 2023 Feb 6]. Available from:https:\/\/www.inspq.qc.ca\/sites\/default\/files\/publications\/2860\u2010surveillance\u2010erreurs\u2010rections\u2010transfusionnelles\u20102019.pdf"},{"key":"e_1_2_9_12_1","unstructured":"Serious Hazards of Transfusion (SHOT).Annual Shot Report 2019. [cited 2023 Feb 6]. Available from:https:\/\/www.shotuk.org\/shot-reports\/report-summary-and-supplement-2019\/"},{"key":"e_1_2_9_13_1","unstructured":"Centers for Disease Control and Prevention.National Healthcare Safety Network Biovigilance Component Hemovigilance Module Surveillance Protocol.2021."},{"key":"e_1_2_9_14_1","unstructured":"Serious Hazards of Transfusion.Definitions of current SHOT reporting categories & what to report.2021[cited 2022 Jan 11]. Available from:https:\/\/www.shotuk.org\/wp-content\/uploads\/myimages\/SHOT-Definitions-V6-19.10.21.pdf"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1974.tb02402.x"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijlh.12176"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1993.tb02529.x"},{"key":"e_1_2_9_18_1","first-page":"723","article-title":"Weak A' phenotypes: relationship between red cell agglutinability and antigen site density","volume":"27","author":"Cartron JP","year":"1974","journal-title":"Immunology"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1994.tb00315.x"},{"key":"e_1_2_9_20_1","unstructured":"Qu\u00e9bec Publications.M\u20109 r. 20.3\u2014R\u00e8glement sur les dossiers les lieux d'exercice et la cessation d'exercice d'un m\u00e9decin. [cited 2022 July 13]. Available from:https:\/\/www.legisquebec.gouv.qc.ca\/fr\/document\/rc\/M-9 %20r.%2020.3"}],"container-title":["Vox Sanguinis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vox.13503","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T14:20:32Z","timestamp":1697293232000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/vox.13503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,17]]},"references-count":19,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.1111\/vox.13503"],"URL":"https:\/\/doi.org\/10.1111\/vox.13503","archive":["Portico"],"relation":{},"ISSN":["0042-9007","1423-0410"],"issn-type":[{"value":"0042-9007","type":"print"},{"value":"1423-0410","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,17]]}}}